Cancer
BX43361
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Trial overview
Topic
Solid tumors
Study details
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Eligibility criteria
General Inclusion Criteria:
- Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
- Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial
Inclusion Criteria for Participants with Stage III NSCLC
- Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
General Exclusion Criteria:
- History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
- Any condition that may affect the interpretation of study results
- Significant liver or cardiovascular disease
- Prior allogenic stem-cell or solid-organ transplantation
Further information
Please click here for more information
Location